Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban plus clopidogrel after PCI in Chinese patients with acute coronary syndrome and atrial fibrillation
ChiCTR2000030143Phase 4Completed
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban and clopidogrel in acute coronary syndrome (ACS), Atrial fibrillation (AFib) and coronary arteriosclerosis, sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: Renal function. Started Jan 2018; status: completed.
02
Drugs
rivaroxabanclopidogrel
03
Conditions
acute coronary syndrome (ACS)Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2000030143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030143.